Меъда ости бези саратонининг сўнгги босқичларида даво усуллари

  • № 2 2018

Страницы: 

19

 – 

21

Язык: узбекский

Открыть файл статьи
Открыть страницу статьи в Интернет

Аннотация

Рак поджелудочной железы считается одним из агрессивных раков, но из-за отсутствия специфических симптомов большинство пациентов обращаются на местно-распространённых стадиях или с метастатическим поражением. Это приводит к затруднению выбора метода лечения и ухудшению результатов лечебных вмешательств. Проводимые лечебные мероприятия улучшают результаты лечения, но прогноз болезни остается неблагоприятним. В настоящее время из-за низкой эффективности традиционного лечения необходима разработка новых методов и внедрение их в практику.

Меъда ости бези саратони агрессив саратон турларидан бири ҳисобаланади, аммо унинг кечишида махсус белгилари мавжуд бўлмаганлиги учун беморлар аксарият ҳолларда маҳаллий тарқалган ёки метастатик касаллик билан мурожаат қилишади. Бу эса даво чорасини танлашдаги ёндашувни қийинлаштиргани ҳолда даволаш натижарини кескин ёмонлашувига олиб келади. Мавжуд даволаш чоралари беморлар умумий яшовчанлигини яхшилагани билан касаллик прогнози ҳануз ўзгаришсиз қолмоқда. Ҳозирги кунда анъанавий даволаш натижаларининг самарасизлиги янги даво чораларини ишлаб чиқишни ва амалиётга тадбиқ этишни талаб этади.

Pancreatic cancer is considered one of the aggressive cancers, but because of the absence of specific symptoms, most patients are treated in locally advanced stages or with metastatic lesions. This leads to difficulties in choosing a method of treatment and worsening the results of treatment interventions. Conducted treatment measures improve the results of treatment, but the disease prognosis remains unfavorable. Currently, due to the low inefficiency of traditional treatment, it is necessary to develop new methods and introduce them into practice.

Список использованных источников

  1. Adamska A., Domenichini A., Falasca M. Pancreatic Ductal Adenocarcinoma: Current andEvolving Therapies // Int. J. Mol. Sci. – 2017. – Vol. 18. – P. 1338.
  2. Carr R.M., Fernandez‐Zapico M.E. Pancreatic cancer microenvironment, to target or not to target? // EMBO Mol. Med. – 2016. – Vol. 8, №2. – P. 80-82.
  3. Conroy Th., Desseigne F. et al. FOLFIRINOX versus Gemcitabine for Metastatic Pancreatic Cancer // New Engl. J. Med. – 2011. – Vol. 364. – P. 1817-1825.
  4. Da Rocha Lino A., Abrahao C.M., Brandao R.M. et al. Role of gemcitabine as second-line therapy after progression on FOLFIRINOX in advanced pancreatic cancer: A retrospective analysis // J. Gastrointest. Oncol. – 2015. – Vol. 6. – P. 511-515.
  5. Eser S., Schnieke A., Schneider G., Saur D. Oncogenic KRAS signalling in pancreatic cancer // Brit. J. Cancer. – 2014. – Vol. 111. – P. 817-822.
  6. Hidalgo M., Cascinu S. et al. Addressing the challenges of pancreatic cancer: future directions for improving outcomes // Pancreatology. – 2013. – Vol. 15. – P. 8-18.
  7. Ilic M., Ilic I. Epidemiology of pancreatic cancer // Wld J. Gastroenterol. – 2016. – Vol. 22 (44). – P. 9694-9705.
  8. Iqbal J., Ragone A., Lubinski J. et al. The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers // Brit. J. Cancer. – 2012. – Vol. 107, №12. – P. 2005-2009.
  9. Johansson H., Andersson R. et al. Immune checkpoint therapy for pancreatic cancer // Wld J. Gastroenterol. – 2016. – Vol. 22 (43). – P. 9457-9476.
  10. Jones S., Zhang X., Parsons D.W. et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses // Science. – 2008. – Vol. 321. – P. 1801-1806.
  11. Kaufman B., Shapira-Frommer R., Schmutzler R.K. et al. Olaparibmonotherapy in patients with advanced cancer anda germline BRCA1/2 mutation // J. Clin. Oncol. – 2015. – Vol. 33. – P. 244-250.
  12. Lindberg J.M., Newhook T.E., Adair S.J. et al. Co-treatment with panitumumaband trastuzumab augments response to the MEK inhibitor trametinib in a patient-derived xenograft model of pancreatic cancer // Neoplasia. – 2014. – Vol.
  13. Matsuoka T., Yashiro M. Molecular targets for the treatment of pancreatic cancer: Clinical and experimental studies // Wld J. Gastroenterol. – 2016. – Vol. 22 (№2). – P. 776-789.
  14. McKenna S., Eatock M. The medical management of pancreatic cancer: A review // The Oncologist. – 2003. – Vol. 8. – P. 149-160.
  15. Moore M.J., Goldstein D., Hamm J. et al. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group // J. Clin. Oncol. – 2007. – Vol. 25. – P. 1960-1966.
  16. Neoptolemos J.P., Stocken D.D., Bassi C. et al. Adjuvant chemotherapy with f luorouracil plus folinic acid vs gemcitabine following pancreatic cancer resection: a randomized controlled trial // J.A.M.A. – 2010. – Vol. 304. – P. 1073-1081.
  17. Oettle H., Neuhaus P., Hochhaus A. et al. Adjuvant chemotherapy with gemcitabine and long-term outcomes among patients with resected pancreatic cancer: the CONKO-001 randomized trial // J.A.M.A. – 2013. – Vol. 310. – P. 1473-1481.
  18. Philip P.A., Zalupski M.M. et al. Phase II study of gemcitabine and cisplatin in the treatment of patients with advanced pancreatic carcinoma // Cancer. – 2001. – Vol. 92, №3. – P. 569-577
  19. Rossi M.L., Rehman A.A., Gondi C.S. Therapeutic options for the management of pancreatic cancer // Wld J. Gastroenterol. – 2014. – Vol. 20 (32). – P. 11142-11159.
  20. Ryan D.P, Theodore S. Hong et al. Pancreatic cancer // New Engl. J. Med. – 2014. – 1039 p.
  21. Siegel R., Naishadham D., Jemal A. Cancer statistics, 2013 // Cancer J. Clin. – 2013. – Vol. 63. – P. 11-30.
  22. Teague A., Lim K.-H., Wang-Gillam A. Advanced pancreatic adenocarcinoma: a review of current treatment strategies and developing therapies // Ther. Adv. Med. Oncol. – 2015. – Vol. 7, №2. – P. 68-84.
  23. Thallinger C., Füreder T., Preusser M. et al. Review of cancer treatment with immune checkpoint inhibitors: Current concepts, expectations, limitations and pitfalls // Wien. Klin. Wochenschr. – 2018. – Bd. 130, №3-4. – S. 85-91.
  24. Ueno H., Ioka T., Ikeda M. et al. Randomized phase III study of gemcitabine plus S-1, S-1 alone, or gemcitabine alone in patients with locally advanced and metastatic pancreatic cancer in Japan and Taiwan: GEST study // J. Clin. Oncol. – 2013. – Vol. 31. – P. 1640-1648.
  25. Vincent A., Herman J., Schulick R. et al. Pancreatic cancer // Lancet. – 2011. – Vol. 378. – P. 607-620.
  26. Von Hoff D.D., Ervin T., Arena F.P. et al. Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine // New Engl. J. Med. – 2013. – Vol. 369. – P. 1691-703.
  27. Winter J.M., Brennan M.F., Tang L.H. et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades // Ann. Surg. Oncol. – 2012. – Vol. 19. – P. 169-175.
  28. Zaanan A., Trouilloud I., Markoutsaki T. et al. FOLFOX as secondline chemotherapy in patients withpretreated metastatic pancreatic cancer from the FIRGEM study // BMC Cancer. – 2014. – Vol. 14. – P. 441.

Список всех публикаций, цитирующих данную статью